Detection of diabetes and intermediate hyperglycaemia, and prevention of type 2 diabetes [0.03%]
糖尿病和前期高血糖的检测以及2型糖尿病的预防
Stephen Colagiuri,Antonio Ceriello;IDF Technical Working Group
Stephen Colagiuri
Management of metabolic dysfunction-associated steatotic liver disease (MASLD) in type 2 diabetes [0.03%]
第7部分:2型糖尿病患者的代谢紊乱相关肝脂肪变性疾病(MAFLD)管理建议
Stephen Colagiuri,Antonio Ceriello;IDF Technical Working Group
Stephen Colagiuri
Stephen Colagiuri,Antonio Ceriello;IDF Technical Working Group
Stephen Colagiuri
Stephen Colagiuri,Antonio Ceriello;IDF Technical Working Group
Stephen Colagiuri
BLOOD GLUCOSE-LOWERING THERAPIES - NON-INSULIN OPTIONS FOR TYPE 2 DIABETES [0.03%]
3. 降血糖治疗措施——用于2型糖尿病的非胰岛素药物选项
Stephen Colagiuri,Antonio Ceriello;IDF Technical Working Group
Stephen Colagiuri
Stephen Colagiuri,Antonio Ceriello;IDF Technical Working Group
Stephen Colagiuri
Predictors of diabetes remission after bariatric surgery in patients with type 2 diabetes mellitus duration ≥ 10 years: A retrospective cohort study [0.03%]
长期患2型糖尿病患者代谢手术后糖尿病缓解的预测因素:回顾性队列研究
Nianrong Zhang,Biao Zhou,Hao Wang et al.
Nianrong Zhang et al.
Objective: Patients with type 2 diabetes mellitus (T2DM) duration ≥ 10 years often have significant β-cell failure. This study aimed to explore predictors of diabetes remission after bariatric surgery in these patients....
IDF global clinical practice recommendations for managing type 2 diabetes - 2025 [0.03%]
国际糖尿病联盟2型糖尿病管理全球临床实践建议-2025
Peter Schwarz
Peter Schwarz
IDF global clinical practice recommendations for managing type 2 diabetes - 2025 [0.03%]
国际糖尿病联合会2型糖尿病管理全球临床实践建议(2025版)
Antonio Ceriello,Stephen Colagiuri
Antonio Ceriello
Stephen Colagiuri,Antonio Ceriello;IDF Technical Working Group
Stephen Colagiuri